Lilly lines up its next shot at Alzheimer’s

Almost $19bn was added to Lilly’s market cap when donanemab met the primary endpoint of Trailblazer-Alz back in January. It will become clearer whether the Alzheimer’s disease project is worthy of the excitement when full results from the trial are presented on March 13 at the medical conference AD/PD 2021.